Open Access

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Congress Session

About the speaker

Professor Stephen Nicholls

Monash Heart, Melbourne (Australia)
36 presentations
1 follower

5 more presentations in this session

Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen

Speaker: Professor S. Nissen (Cleveland, US)

Thumbnail

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

Speaker: Professor T. Pedersen (Oslo, NO)

Thumbnail

Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial

Speaker: Professor E. Lonn (Hamilton, CA)

Thumbnail

One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

Speaker: Doctor V. Roolvink (Zwolle, NL)

Thumbnail

Access the full session

Clinical Trial Update 2

Speakers: Professor S. Nicholls, Professor S. Nissen, Professor T. Pedersen, Professor S. Verma, Professor E. Lonn...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk